A detailed history of Legacy Capital Group California, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Legacy Capital Group California, Inc. holds 1,041 shares of BIIB stock, worth $237,420. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,041
Previous 976 6.66%
Holding current value
$237,420
Previous $253 Million 11.12%
% of portfolio
0.08%
Previous 0.1%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$212.02 - $267.71 $13,781 - $17,401
65 Added 6.66%
1,041 $224 Million
Q4 2023

Feb 08, 2024

BUY
$222.59 - $267.94 $24,484 - $29,473
110 Added 12.7%
976 $253 Million
Q3 2023

Nov 06, 2023

BUY
$253.3 - $285.89 $28,369 - $32,019
112 Added 14.85%
866 $223 Million
Q2 2023

Aug 10, 2023

BUY
$275.25 - $318.06 $207,538 - $239,817
754 New
754 $215 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $32.8B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Legacy Capital Group California, Inc. Portfolio

Follow Legacy Capital Group California, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legacy Capital Group California, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Legacy Capital Group California, Inc. with notifications on news.